dihydroergotamine intranasal (STS101) / Shin Nippon Biomedical Labs, Satsuma Pharma  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
dihydroergotamine intranasal (STS101) / Shin Nippon Biomedical Labs
NCT03874832: A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects

Completed
1
46
US
Dihydroergotamine, Dihydroergotamine Mesylate
Satsuma Pharmaceuticals, Inc.
Migraine With Aura, Migraine Without Aura, Migraine
11/18
11/18
NCT05337254: A Study of the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects

Completed
1
36
US
Dihydroergotamine, Dihydroergotamine Mesylate
Satsuma Pharmaceuticals, Inc.
Migraine, Migraine With Aura, Migraine Without Aura
06/21
06/21

Download Options